STAAR Surgical to Host Investor Breakfast and Webcast during the American Academy of Ophthalmology's Annual Meeting

  STAAR Surgical to Host Investor Breakfast and Webcast during the American
                  Academy of Ophthalmology's Annual Meeting

PR Newswire

MONROVIA, Calif., Nov. 14, 2013

MONROVIA, Calif., Nov. 14, 2013 /PRNewswire/ --STAAR Surgical Company
(NASDAQ: STAA), a leading developer, manufacturer and marketer of minimally
invasive ophthalmic products, today announced that it is hosting an investor
breakfast and webcast on Saturday, November 16 during the American Academy of
Ophthalmology (AAO) Annual Meeting in New Orleans, LA.

Dr. Erik Mertens, Medical Director and founder of the Medipolis Eye Centre in
Antwerp, Belgium, will provide an update on his results from the Visian ICL
CentraFLOW technology as well as the benefits his patients are receiving. The
CentraFLOW technology has been a key driver in the 35% ICL procedure growth in
Europe during the first nine months of 2013. Dr. Mertens will also present
his data on the procedure time savings, which he expects from the Preloaded
Visian ICL that will begin commercialization in Europe early next year.

Barry G. Caldwell, STAAR's President & CEO, will provide a brief update on the
Company's operational progress, upcoming catalysts, as well as an overview of
STAAR's latest product under development, the Visian V6 models, which are
designed to treat the stages of presbyopia. Presbyopia is a progressive loss
of the ability for the natural lens to focus on objects near.

Investors participating in AAO and interested in attending the breakfast
meeting, should contact Leigh Salvo at lsalvo@evcgroup.com or call (415)
568-9348. A live audio webcast of the presentation will be available at 5:00
a.m. PT/7:00 a.m. CT/8:00 a.m. ET from the investor section of the Company's
website at www.staar.com/html/investor-info.html. The webcast will also be
archived and available for 90 days following the event.

About STAAR Surgical
STAAR, which has been dedicated solely to ophthalmic surgery for over 25
years, designs, develops, manufactures and markets implantable lenses for the
eye and delivery systems therefor. All of these lenses are foldable, which
permits the surgeon to insert them through a small incision. STAAR's lens used
in refractive surgery as an alternative to LASIK is called an Implantable
Collamer® Lens or "ICL." A lens used to replace the natural lens after
cataract surgery is called an intraocular lens or "IOL." Over 375,000 Visian
ICLs have been implanted to date; to learn more about the ICL go to:
www.visianinfo.com. STAAR has approximately 300 full time employees and
markets lenses in over 60 countries. Headquartered in Monrovia, CA, it
manufactures in the following locations: Nidau, Switzerland; Aliso Viejo, CA;
and Monrovia, CA. For more information, please visit the Company's website at
www.staar.com.

Collamer® is the registered trademark for STAAR's proprietary biocompatible
collagen copolymer lens material.

Safe Harbor
All statements in this press release that are not statements of historical
fact are forward-looking statements, including statements about any of the
following: the plans, strategies, and objectives of management for future
operations or prospects for achieving such plans, including but not limited
to, statements regarding new products, CE Mark approval and launch of the
Visian ICL Preloaded System, and plans for the Visian V6, as well as
expectations for success of these products in the U.S. or international
markets or government approval of them, and any statements of assumptions
underlying any of the foregoing. These statements are based on expectations
and assumptions as of the date of this press release and are subject to
numerous risks and uncertainties, which could cause actual results to differ
materially from those described in the forward-looking statements. Important
additional factors that could cause actual results to differ materially from
those indicated by such forward-looking statements are set forth in the
company's Annual Report on Form 10-K for the year ended December 28, 2012,
under the caption "Risk Factors," which is on file with the Securities and
Exchange Commission and available in the "Investor Information" section of the
company's website under the heading "SEC Filings."

CONTACT: Investors                 Media
         EVC Group                 EVC Group
         Doug Sherk, 415-652-9100  Janine McCargo
         Leigh Salvo, 415-568-9348 646-688-0425

SOURCE STAAR Surgical Company

Website: http://www.staar.com
Website: http://visianinfo.com
 
Press spacebar to pause and continue. Press esc to stop.